Equity Compensation Creates Opportunity—and Complexity
In San Diego’s biotech and life‑science sector, compensation is rarely simple. While base income may be predictable, equity compensation—often stock options rather than RSUs—becomes the primary driver of long‑term wealth, and the primary source of complexity.
- 20+ years advising San Diego professionals
- Forbes Best-In-State 2023–2025
- Educational content — no product pitch inside
Stock options, restricted stock, and incentive grants can create real opportunity, but without coordination they can also introduce concentration risk, AMT exposure on option exercises, and liquidity questions unique to earlier‑stage or private companies.
Where Complexity Quietly Builds
Many biotech professionals find themselves in a familiar position: income is strong, benefits are generous, yet personal balance sheets feel surprisingly fragile given the effort involved.
The reason is rarely investment performance. More often, it’s a lack of coordination—equity decisions made in isolation, tax events triggered reactively, and long‑term planning deferred until vesting or an exercise deadline forces action.
A Coordinated Planning Approach
At BAS Financial, planning for biotech professionals focuses on how equity decisions interact with the rest of your financial life—cash flow, retirement planning, tax‑efficient diversification, and risk management.
The objective is not to time markets or chase performance, but to replace reaction‑based decisions with intentional strategy.
Credentials
MBA · LUTCF® · CLU® · ChFC® · WMCP® · CEPA™ · CLTC® · AIF®
Not a sales pitch
This is educational content, not individualized advice. There's no product pitch inside—just a starting point for a better-informed conversation.
What Happens After You Request Your Complimentary Review
A conversation about your equity. We talk through your income, equity compensation, and existing retirement accounts—including anything with vesting schedules, exercise deadlines, or tax complexity.
A walkthrough of the gaps. We look at whether your 401(k), IRA, and equity comp are actually working together toward the same goal.
A written summary and next steps. You leave with a plain‑English summary and specific next steps, tailored to your situation.
No obligation, no pressure—the review is designed to answer one question: is there a real gap here worth addressing.
Many Biotech Professionals Are H.E.N.R.Y.s
High income, but wealth concentrated in one employer or one stock—the San Diego H.E.N.R.Y. Checklist walks through the decisions worth reviewing before year end.
Get the H.E.N.R.Y. ChecklistPrefer to Talk It Through Directly?
Is your equity strategy intentional—or simply inherited from your employer's compensation structure? A conversation can help clarify which.
Start a Conversation